Absolute and Relative Quantification of Placenta-specific Micrornas in Maternal Circulation with Placental Insufficiency-related Complications
Overview
Pathology
Affiliations
Placental insufficiency-related complications are one of the leading causes of maternal and perinatal morbidity and mortality. This study investigated the quantification of placenta-specific microRNAs (miRNAs) in the maternal circulation during gestation in a cohort of women with normally progressing pregnancies, the differentiation between placental insufficiency-related complications and normally progressing pregnancies, and the differentiation between placental insufficiency and normally progressing pregnancies during the early stages of gestation. Both absolute and relative quantification of placenta-specific miRNAs (ie, miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525, and miR-526a) was determined in 50 women with normally progressing pregnancies, 32 with complicated pregnancies [21 with preeclampsia with or without intrauterine growth retardation (IUGR) and 11 with IUGR], and 7 women with pregnancies at various gestational stages who later developed preeclampsia and/or IUGR using real-time PCR and a comparative C(T) method relative to normalization factor (ie, geometric mean of ubiquitous miR-16 and let-7d). Both quantification approaches revealed significant increases in extracellular placenta-specific miRNA levels over time in women with normally progressing pregnancies; however, they were not able to differentiate between normally progressing and complicated pregnancies at the time of preeclampsia and/or IUGR onset. Nevertheless, significant elevation of extracellular miRNA levels was observed during early gestation (ie, within the 12th to 16th weeks) in pregnancies with later onset of preeclampsia and/or IUGR. Early gestation extracellular miRNA screening can differentiate between women with normally progressing pregnancies and those who may later develop placental insufficiency-related complications.
Kolawole E, Duggirala A, Gronow O, Wisniewska A, Hu J, Tan B Life (Basel). 2025; 15(2).
PMID: 40003576 PMC: 11856715. DOI: 10.3390/life15020167.
Feng X, Yang C, Wang T, Zhang J, Zhou H, Ma B Cells. 2025; 14(2).
PMID: 39851515 PMC: 11764194. DOI: 10.3390/cells14020087.
Diagnosis, Prevention, and Management of Fetal Growth Restriction (FGR).
Tsikouras P, Antsaklis P, Nikolettos K, Kotanidou S, Kritsotaki N, Bothou A J Pers Med. 2024; 14(7).
PMID: 39063953 PMC: 11278205. DOI: 10.3390/jpm14070698.
Bakhireva L, Solomon E, Roberts M, Ma X, Rai R, Wiesel A Int J Mol Sci. 2024; 25(5).
PMID: 38473937 PMC: 10932119. DOI: 10.3390/ijms25052690.
Circulating miRNAs and Preeclampsia: From Implantation to Epigenetics.
Giannubilo S, Cecati M, Marzioni D, Ciavattini A Int J Mol Sci. 2024; 25(3).
PMID: 38338700 PMC: 10855731. DOI: 10.3390/ijms25031418.